SCHEMBL7785349

SCHEMBL7785349

Cc1cc(I)ccc1Nc1ccc(Br)cc1C(=O)NCCN(C(C)C)C(C)C.Cc1cc(I)ccc1Nc1ccc(F)cc1C(=O)NCCCN1CCCCC1.Cc1cc(I)ccc1Nc1ccc(F)cc1C(=O)NCCN1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
KMT2A Q03164 2/20 0.43
TSHR P16473 4/20 0.42
BCL3 P20749 3/20 0.40
PDGFRB P09619 1/20 0.40
KIT P10721 1/20 0.40
KDR P35968 1/20 0.40
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
PKM P14618 1/20 0.40
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GLA P06280 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7787393 0.85 SMN1; SMN2 (0.44) LMNAKMT2ATSHRBCL3ALDH1A1
SCHEMBL8169156 0.84 KMT2A (0.56) LMNAKMT2ATSHRBCL3PDGFRB
SCHEMBL6035808 0.83 ABL1 (0.55) LMNAKMT2ATSHRBCL3ABL1
SCHEMBL6035410 0.83 MKNK2 (0.45) KMT2APDGFRBKITKDR
SCHEMBL6035719 0.83 BCL3 (0.55) KMT2ABCL3ALDH1A1
SCHEMBL6035840 0.83 LMNA (0.48) LMNAKMT2ATSHRALDH1A1
SCHEMBL6035295 0.81 CYP1A2 (0.51) KMT2AABL1RIN1ALDH1A1NPSR1
SCHEMBL6036039 0.81 CYP1A2 (0.51) KMT2ABCL3PDGFRBKITKDR
SCHEMBL6036408 0.80 CYP1A2 (0.49) LMNAKMT2AABL1RIN1NPSR1
SCHEMBL6035676 0.80 CYP1A2 (0.49) KMT2ABCL3PDGFRBKITKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1143957-A3 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-02-27 EP disclosed
EP-1143957-A2 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-17 EP disclosed
EP-1140067-A1 ANTIVIRAL METHOD USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-10 EP disclosed
EP-1140062-A2 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-10 EP disclosed
EP-1140046-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2001-10-10 EP disclosed
EP-1140291-A1 COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR WARNER-LAMBERT COMPANY LLC (US) 2001-10-10 EP disclosed
WO-2000037141-A9 COMBINATION CHEMOTHERAPY WARNER LAMBERT CO (US) 2000-12-07 WO disclosed
WO-2000040237-A1 ANTIVIRAL METHOD USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-13 WO disclosed
WO-2000040235-A2 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-13 WO disclosed
WO-2000037141-A1 COMBINATION CHEMOTHERAPY WARNER-LAMBERT COMPANY (US) 2000-06-29 WO disclosed
WO-2000035435-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2000-06-22 WO disclosed
WO-2000035436-A2 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-06-22 WO disclosed